KRW 5130.0
(-1.35%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 133.18 Billion KRW | -23.15% |
2022 | 173.29 Billion KRW | 11.4% |
2021 | 155.56 Billion KRW | 114.7% |
2020 | 72.45 Billion KRW | 59.52% |
2019 | 45.42 Billion KRW | 86.36% |
2018 | 24.37 Billion KRW | 33.35% |
2017 | 18.27 Billion KRW | 83.4% |
2016 | 9.96 Billion KRW | 43.45% |
2015 | 6.94 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 120.89 Billion KRW | -2.6% |
2024 Q1 | 124.12 Billion KRW | -6.81% |
2023 Q2 | 155.86 Billion KRW | -8.97% |
2023 FY | 133.18 Billion KRW | -23.15% |
2023 Q4 | 133.18 Billion KRW | -4.69% |
2023 Q3 | 139.73 Billion KRW | -10.35% |
2023 Q1 | 171.22 Billion KRW | -1.2% |
2022 Q2 | 202.18 Billion KRW | -4.05% |
2022 FY | 173.29 Billion KRW | 11.4% |
2022 Q4 | 173.29 Billion KRW | -15.77% |
2022 Q3 | 205.75 Billion KRW | 1.77% |
2022 Q1 | 210.71 Billion KRW | 35.46% |
2021 Q4 | 155.56 Billion KRW | 13.0% |
2021 Q2 | 77.12 Billion KRW | 0.14% |
2021 Q1 | 77.01 Billion KRW | 6.29% |
2021 FY | 155.56 Billion KRW | 114.7% |
2021 Q3 | 137.66 Billion KRW | 78.5% |
2020 Q3 | 67.12 Billion KRW | -1.06% |
2020 Q1 | 44.86 Billion KRW | -1.21% |
2020 FY | 72.45 Billion KRW | 59.52% |
2020 Q2 | 67.84 Billion KRW | 51.21% |
2020 Q4 | 72.45 Billion KRW | 7.94% |
2019 Q3 | 47.72 Billion KRW | 0.0% |
2019 FY | 45.42 Billion KRW | 86.36% |
2019 Q4 | 45.42 Billion KRW | -4.83% |
2019 Q1 | - KRW | -100.0% |
2018 Q4 | 24.37 Billion KRW | 0.0% |
2018 FY | 24.37 Billion KRW | 33.35% |
2017 FY | 18.27 Billion KRW | 83.4% |
2016 FY | 9.96 Billion KRW | 43.45% |
2015 FY | 6.94 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Osang Healthcare Co.,Ltd | 320.54 Billion KRW | 58.45% |
InBody Co.,Ltd | 274.45 Billion KRW | 51.472% |
Curexo Inc. | 107.36 Billion KRW | -24.045% |
Seegene, Inc. | 1251.45 Billion KRW | 89.357% |
i-SENS, Inc. | 498.81 Billion KRW | 73.299% |
Ray Co., Ltd. | 259.55 Billion KRW | 48.686% |
Gencurix Inc. | 33.5 Billion KRW | -297.551% |
L&C Bio Co., Ltd | 262.23 Billion KRW | 49.21% |